|
Patent landscape, scope, and claims: |
US Patent 9,701,709: Scope, Claim Coverage, and Practical Patent-Positioning
United States Patent 9,701,709 is a polymorph-and-solvate patent built around a specific solid-state identification package: X-ray powder diffraction (XRPD) peak sets (CuKα) plus, in one case, a glass transition temperature (Tg ~153°C). The claims then “lift” those solid forms into composition and method-of-use coverage, including broad administration routes and multiple dosage forms.
What does the patent claim, at a technical level?
Core subject matter
The claims are directed to polymorphic forms of “a compound of the formula” (the formula is not provided in the claim text you supplied), with identification defined by:
- Claim 1: A polymorphic form defined by a XRPD halo peak at about 14° 2θ (CuKα) and a Tg of about 153°C.
- Claims 2-5: Solvates defined by specific XRPD peak positions (CuKα).
- Claim 2 solvate: peaks at ~5.6, 10.6, 14.6° 2θ
- Claim 3 solvate: peaks at ~7.0, 7.8, 11.9, 13.9 (double peak), 16.0° 2θ
- Claim 4 acetonitrile hemisolvate: peaks at ~7.5, 15.6, 16.6° 2θ
- Claim 5 solvate: peaks at ~9.3, 9.5, 10.5, 13.6, 15.6° 2θ
How broad the solid-state definitions are
The patent uses peak-position recitations rather than structural property recitations. In practice, this creates a two-tier scope:
- If a competitor’s material can be shown (by XRPD) to match the recited peak set within allowable tolerances, the form can fall within the claim even if the manufacturing process differs.
- If the competitor’s XRPD pattern differs by enough to break the “about” peak matching, the material can avoid literal coverage, but may still face arguments under doctrine-of-equivalents depending on prosecution history and claim construction.
Because Claim 1 includes both XRPD (halo ~14°) and Tg ~153°C, it is inherently more constrained than the purely XRPD-defined solvate claims.
How do the claims expand beyond the solid form?
Composition claims
- Claim 6: A pharmaceutical composition with an active ingredient that consists of the polymorphic form of Claim 1, plus a pharmaceutically acceptable carrier.
- “Consists of” is a meaningful limiter: it signals the active ingredient should be exclusively the Claim 1 polymorph (not a mixture that includes other polymorphs/solvates as the “active ingredient”). In enforcement, this becomes a formulation-level battleground (what counts as the “active ingredient” and whether trace impurities/other forms are present).
Administration-route coverage
- Claims 7 and 8 expand the composition claim into extremely broad route coverage:
- Claim 7 lists a long menu of administration routes, including oral, intramuscular, intravenous, inhalation, topical, and many specialized routes.
- Claim 8 narrows back down to: oral, intraarterial, intravenous or topical.
In litigation posture, this means once a product is captured as a composition meeting Claim 6, route rarely becomes a design-around. Most competitive product formats already fall within “oral” or “topical” or “injectable.”
Dosage-form coverage
- Claim 10 lists dosage formats: hard/soft capsules, tablets, syrup, suspension, emulsion, solution, solid dispersion, wafer, elixir.
Claims 11-12 cover topical preparations specifically (lotion, cream, gel, ointment, salve, etc.).
Active-content range
- Claim 13: active ingredient amount about 0.01% to about 5% by weight.
This is a quantitative limiter. Many small-molecule oral formulations will sit inside this band, but high-dose or concentrated topical/implantable formats may fall outside depending on how the active is expressed “by weight” in the final dosage.
What therapeutic use does the patent cover?
Method-of-treatment claim
- Claim 14: treating a condition associated with inflammation or oxidative stress, selected from:
- prostate cancer, dermatitis, sepsis, pulmonary inflammation, pulmonary fibrosis, COPD, asthma, mucositis, ocular inflammation
- The method requires administering a therapeutically effective amount of the polymorphic form of Claim 1.
Specific dependent use
- Claim 15: condition is dermatitis.
Practical scope implications
This is use-based coverage that is:
- broad in disease selection (8 enumerated indications),
- broad in mechanistic framing (inflammation or oxidative stress), and
- tied to the specific polymorphic form of Claim 1, not the solvates of Claims 2-5.
So a competitor who uses a different solid form (e.g., a solvate of Claims 2-5) may still face composition or solid-form coverage arguments, but Claim 14 method enforcement is keyed to Claim 1 polymorph as written.
Where is the enforceable “center of gravity”?
The strongest and most enforceable linkage is:
- Claim 1 defines the protected polymorph.
- Claims 6-15 repeatedly depend on that Claim 1 polymorph for pharmaceutical composition and method-of-use.
Claims 2-5 define other solvates/hemisolvate, but there is no explicit downstream composition or method-of-use claim shown in your excerpt that clearly ties to Claims 2-5 polymorphs as active ingredients. Based on the text you provided, the claims that extend to formulation and methods are built on Claim 1.
What would a competitor need to avoid to reduce infringement risk?
Design-around strategies implied by the claim text
- Avoid using the Claim 1 polymorph (the XRPD halo ~14° 2θ and Tg ~153°C package).
- If using solvates, ensure they correspond to Claims 2-5 only, and do not generate or convert into the Claim 1 polymorph during manufacturing, storage, or use.
- Route and dosage form are unlikely to be successful design-around levers if the drug is already delivered orally or topically or via injectable administration; the claim set is deliberately broad.
- Dose strength/content could be a lever for Claim 13 if commercial formulations systematically exceed or fall below 0.01% to 5% by weight.
Patent landscape logic: how this patent sits in a typical solid-state strategy
Without bibliographic data (patent title, assignee, priority dates, related family members, or prosecution history), the landscape analysis must be limited to what the claim set structurally implies: this is a solid-state IP block that competitors typically confront via:
- alternative polymorph/solvate development,
- deliberate stabilization of an alternative solid form, and/or
- formulation strategies that keep the solid form from converting to the patented polymorph under relevant conditions (humidity, heat, dissolution state).
This patent’s claim structure suggests it was built to protect not only the crystallographic “fingerprint,” but also a property-based identifier (Tg) for the primary polymorph.
Claim-by-claim scope map (what each claim covers)
| Claim |
What is claimed |
Solid-state identifier |
Downstream coverage |
| 1 |
Polymorphic form of compound |
XRPD (CuKα): halo peak ~14° 2θ; Tg ~153°C |
Anchors method and composition via dependent claims |
| 2 |
Polymorphic form as a solvate |
XRPD peaks ~5.6, 10.6, 14.6° 2θ |
Solid-form protection only (per excerpt) |
| 3 |
Polymorphic form as a solvate |
XRPD peaks ~7.0, 7.8, 11.9, 13.9 (double), 16.0° 2θ |
Solid-form protection only (per excerpt) |
| 4 |
Polymorphic form as acetonitrile hemisolvate |
XRPD peaks ~7.5, 15.6, 16.6° 2θ |
Solid-form protection only (per excerpt) |
| 5 |
Polymorphic form as a solvate |
XRPD peaks ~9.3, 9.5, 10.5, 13.6, 15.6° 2θ |
Solid-form protection only (per excerpt) |
| 6 |
Pharmaceutical composition |
Active ingredient is polymorphic form of Claim 1 |
Composition |
| 7 |
Composition route expansion |
Depends on Claim 6 |
Broad routes |
| 8 |
Route subset |
Depends on Claim 7 |
Oral / intraarterial / intravenous / topical |
| 9 |
Oral subset |
Depends on Claim 7 |
Oral |
| 10 |
Dosage forms |
Depends on Claim 6 |
Capsules/tablets/liquids/solids/dispersion |
| 11-12 |
Topical formats |
Depends on Claim 11 |
Lotion/cream/gel/oil/ointment/etc. |
| 13 |
Active-content range |
Depends on Claim 6 |
0.01% to 5% by weight |
| 14 |
Method of treating inflammation/oxidative stress |
Administer Claim 1 polymorph |
Prostate cancer, dermatitis, sepsis, pulmonary inflammation, fibrosis, COPD, asthma, mucositis, ocular inflammation |
| 15 |
Dependent indication |
Depends on Claim 14 |
Dermatitis |
How “about” could affect claim reach
Every XRPD peak and Tg is qualified by “about.” In enforcement, that typically shifts the dispute to:
- the instrumental set-up (CuKα source is specified),
- sample preparation (as-received vs milled, hydration state),
- peak assignment methodology, and
- whether missing peaks or extra peaks matter.
The claim language uses a mixture of:
- single features (Claim 1 halo and Tg),
- multi-peak sets (Claims 2-5),
- plus Tg (Claim 1 only).
In practice, the multi-peak solvate claims are more diagnostic and harder to replicate by accident, but they may be easier to design around by selecting a different solvate form.
Key takeaways
- US 9,701,709 is a solid-state patent built on XRPD fingerprints (CuKα peak positions) and one Tg anchor (Claim 1: ~153°C).
- Claims 6-15 concentrate enforceable use and product coverage on Claim 1’s polymorphic form (not Claims 2-5 solvates).
- Administration routes and dosage forms are broad and likely not meaningful design-around levers if the product is already within oral/injectable/topical formats.
- Claim 13 adds a quantitative formulation constraint (0.01% to 5% by weight) that can matter for product-specific infringement assessment.
- Avoiding the Claim 1 polymorph is the most direct risk-reduction approach; alternative solvates matter mainly insofar as they prevent formation/conversion to the Claim 1 form in storage and use.
FAQs
1) What is the single most important claim for enforcement?
Claim 1, because it is the anchor polymorph that is incorporated into Claim 6 (composition) and Claim 14 (method-of-treatment).
2) Do Claims 2-5 also control pharmaceutical composition or method coverage?
In the excerpt provided, the composition and method claims explicitly tie to the polymorphic form of Claim 1. Claims 2-5 define additional solid forms but are not shown in your text as the active ingredient for the downstream claims.
3) Can a competitor use another solvate and still be infringing?
If the competitor’s product converts to the Claim 1 polymorph during manufacturing, storage, or use, infringement risk increases. If it stays as a different solvate and does not include the Claim 1 polymorph as the active form, risk is reduced relative to Claim 1-based claims.
4) Is route a meaningful design-around?
Not in most cases. The patent lists many routes in Claim 7, and Claim 8 covers oral, intraarterial, intravenous, and topical.
5) What is the numerical constraint that can limit coverage for products?
Claim 13, which limits the active ingredient to about 0.01% to about 5% by weight in the pharmaceutical composition.
References
[1] United States Patent No. 9,701,709 (claims text provided in prompt).
More… ↓
⤷ Start Trial
|
